Product Name :
U-44069
Description:
EC50: 3 μM and 54 nM for platelet aggregation and phosphatidate formation in human platelets, respectively U-44069 is a TP receptor agonist. Increased production of vasoconstrictive prostanoids, such as thromboxane A2, contributes to endothelial dysfunction and increased hepatic vascular tone in cirrhosis. Thromboxane A2 induces vasoconstriction via activation of the thromboxane-A2 /prostaglandin-endoperoxide (TP) receptor. In vitro: In a previous study, dose-response relationships for raised cytoplasmic free calcium concentration and shape change were simultaneously measured. With the calcium ionophore ionomycin the threshold of free calcium concentration for shape change was 300 nM with a maximal response at 800 nM. With 1 mM external free calcium concentration the U44069 concentrations required to stimulate half-maximal shape change and an increase in free calcium concentration were 2 and 41 nM, respectively. Low levels of U44069 could evoke substantial shape change without any rise in free calcium concentration. In the absence of external calcium, U44069 was able to stimulate half-maximal shape change at 2 nM, and half-maximal elevation of free calcium concentration at 69 nM . In vivo: Animal study showed that naive mice treated with either U-44069 at 25 or 100 μg/kg (iv), endothelin-1 (100 pmol, intranasally) or the ET B receptor agonist IRL-1620 (100 pmol, intranasally) had a marked increase in airway reactivity to carbachol .{{Blinatumomab} web|{Blinatumomab} CD19|{Blinatumomab} Biological Activity|{Blinatumomab} Description|{Blinatumomab} custom synthesis|{Blinatumomab} Autophagy} Clinical trial: So far, no clinical study has been conducted.
CAS:
56985-32-1
Molecular Weight:
350.49
Formula:
C21H34O4
Chemical Name:
(5Z)-7-[(5S,6R)-5-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-2-oxabicyclo[2.2.1]heptan-6-yl]hept-5-enoic acid
Smiles :
CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(O)=O)C2CC1CO2
InChiKey:
DJKDIKIDYDXHDD-REGKDVDGSA-N
InChi :
InChI=1S/C21H34O4/c1-2-3-6-9-17(22)12-13-18-16-14-20(25-15-16)19(18)10-7-4-5-8-11-21(23)24/h4,7,12-13,16-20,22H,2-3,5-6,8-11,14-15H2,1H3,(H,23,24)/b7-4-,13-12+/t16?,17-,18-,19+,20?/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Dihydromethysticin} site|{Dihydromethysticin} Metabolic Enzyme/Protease|{Dihydromethysticin} Technical Information|{Dihydromethysticin} In Vivo|{Dihydromethysticin} custom synthesis|{Dihydromethysticin} Autophagy}
Shelf Life:
≥12 months if stored properly.PMID:24211511
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
EC50: 3 μM and 54 nM for platelet aggregation and phosphatidate formation in human platelets, respectively U-44069 is a TP receptor agonist. Increased production of vasoconstrictive prostanoids, such as thromboxane A2, contributes to endothelial dysfunction and increased hepatic vascular tone in cirrhosis. Thromboxane A2 induces vasoconstriction via activation of the thromboxane-A2 /prostaglandin-endoperoxide (TP) receptor. In vitro: In a previous study, dose-response relationships for raised cytoplasmic free calcium concentration and shape change were simultaneously measured. With the calcium ionophore ionomycin the threshold of free calcium concentration for shape change was 300 nM with a maximal response at 800 nM. With 1 mM external free calcium concentration the U44069 concentrations required to stimulate half-maximal shape change and an increase in free calcium concentration were 2 and 41 nM, respectively. Low levels of U44069 could evoke substantial shape change without any rise in free calcium concentration. In the absence of external calcium, U44069 was able to stimulate half-maximal shape change at 2 nM, and half-maximal elevation of free calcium concentration at 69 nM . In vivo: Animal study showed that naive mice treated with either U-44069 at 25 or 100 μg/kg (iv), endothelin-1 (100 pmol, intranasally) or the ET B receptor agonist IRL-1620 (100 pmol, intranasally) had a marked increase in airway reactivity to carbachol . Clinical trial: So far, no clinical study has been conducted.|Product information|CAS Number: 56985-32-1|Molecular Weight: 350.49|Formula: C21H34O4|Chemical Name: (5Z)-7-[(5S,6R)-5-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-2-oxabicyclo[2.2.1]heptan-6-yl]hept-5-enoic acid|Smiles: CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(O)=O)C2CC1CO2|InChiKey: DJKDIKIDYDXHDD-REGKDVDGSA-N|InChi: InChI=1S/C21H34O4/c1-2-3-6-9-17(22)12-13-18-16-14-20(25-15-16)19(18)10-7-4-5-8-11-21(23)24/h4,7,12-13,16-20,22H,2-3,5-6,8-11,14-15H2,1H3,(H,23,24)/b7-4-,13-12+/t16?,17-,18-,19+,20?/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|
